e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Biomarkers and exacerbations of asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy of roflumilast in the frequent exacerbation COPD phenotype
J. Wedzicha, K. Rabe, P. Calverley, F. Martinez, D. Bredenbröker, M. Brose, U. M. Goehring (London, Liverpool, United Kingdom; Grosshansdorf, Konstanz, Germany; Ann Arbor, United States Of America)
Source:
Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Session:
Biomarkers and exacerbations of asthma and COPD
Session type:
Poster Discussion
Number:
3355
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
J. Wedzicha, K. Rabe, P. Calverley, F. Martinez, D. Bredenbröker, M. Brose, U. M. Goehring (London, Liverpool, United Kingdom; Grosshansdorf, Konstanz, Germany; Ann Arbor, United States Of America). Efficacy of roflumilast in the frequent exacerbation COPD phenotype. Eur Respir J 2011; 38: Suppl. 55, 3355
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Long-term effect of roflumilast on exacerbations in patients with severe to very severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 526s
Year: 2006
Comparison of fluticasone, roflumilast and tiotropium in a model of influenza-induced acute COPD exacerbation
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability
Source: International Congress 2014 – Markers
Year: 2014
Assessment of efficacy and tolerability of roflumilast add-on to LABA/LAMA/ICS in the treatment of COPD in Indian patients
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Clinical efficacy of nebulised budesonide in acute exacerbation of COPD
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010
Clinical effectiveness of nebulized budesonide in the treatment of acute asthma and exacerbations of chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2001; 18: Suppl. 33, 146s
Year: 2001
Effects of roflumilast in highly symptomatic COPD patients
Source: Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care
Year: 2012
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Montelukast as add-on therapy in severe noninfectious COPD exacerbations
Source: Eur Respir J 2003; 22: Suppl. 45, 241s
Year: 2003
Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015
The effect of tiotropium/olodaterol versus tiotropium on COPD exacerbation rates in patients with/without frequent exacerbation history
Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases
Year: 2019
Efficacy of roflumilast with concomitant cardiovascular medication in patients with COPD
Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management
Year: 2013
Roflumilast N-oxide combined with PI3Kδ inhibitor improves the phenotype of early-onset COPD
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016
Efficacy of the PDE4 inhibitor roflumilast in COPD patients with chronic bronchitis
Source: Annual Congress 2009 - Treatment of COPD
Year: 2009
The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Baseline characteristics of COPD patients with frequent COPD exacerbations in tiotropium trials
Source: Eur Respir J 2006; 28: Suppl. 50, 175s
Year: 2006
Clinical and functional effectiveness of roflumilast in severe COPD patients
Source: Annual Congress 2013 –Modern approach to various clinical settings
Year: 2013
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease
Source: Eur Respir J 2003; 21: 74-81
Year: 2003
Once-daily QVA149 reduces exacerbations and improves health status in comparison with glycopyrronium and tiotropium in patients with severe-to-very severe COPD: The SPARK study
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept